Anti-Viral Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

The Anti-viral Therapeutics Market has been Segmented by Drug Type (Herpes Anti-viral Drugs, Hepatitis Anti-viral Drugs, HIV Anti-viral Drugs, Influenza Anti-viral Drugs, and Other Anti-viral Drugs), Distribution Channel, and Geography.

Market Snapshot

Study Period:


Base Year:


Fastest Growing Market:

Asia Pacific

Largest Market:

North America


6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The anti-viral therapeutics market is expected to register a CAGR of 6.0%, over the forecast period. North America dominates the market, owing to the growing prevalence of hepatitis C and human immunodeficiency viruses (HIV) infections, coupled with the presence of a huge patient pool suffering from virally infectious diseases.

  • In order to combat drug resistance, the combination of various anti-virals with different mechanisms of action is used. Combination antiviral therapy is the standard of care in HIV and hepatitis C virus infections, and it is likely to become increasingly used in other viral infections.
  • Anti-viral therapeutics are commercially available for diseases, like influenza, hepatitis C, chickenpox, papilloma, and AIDS. Additionally, there is increasing adoption of nucleoside and nucleotide analogues as first-line anti-virals. Based on the current development pipeline, many small molecule-based anti-viral drugs (like interferons and other similar small protein analogues) are expected to receive their marketing approvals.

Scope of the Report

The market for anti-viral therapeutics has been considered according to the burden of the disease caused by viruses at the global level. The anti-viral therapeutics market is essentially split into anti-viral drug markets for herpes, hepatitis, HIV, and influenza, among other diseases. The market has also been segmented on the basis of distribution channels into hospital pharmacy, independent pharmacy, and online drug stores.

By Drug Type
Herpes Anti-viral Drugs
Hepatitis Anti-viral Drugs
HIV Anti-viral Drugs
Influenza Anti-viral Drugs
Other Anti-viral Drugs
By Distribution Channel
Hospital Pharmacy
Independent Pharmacy and Drug Store
Online Pharmacy
By Geography
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

By Drug Type, HIV Anti-viral Drugs Mainly Boost the Global Market

HIV is a major global public health issue. According to the 2019 UNAIDS data, 24.5 million people were accessing antiretroviral therapy by the end of 2019. About 1.7 million people became newly infected with the virus in 2018. The vast majority of people living with HIV are located in low- and middle-income countries, with an estimated 66% living in Sub-Saharan Africa. However, the majority of HIV anti-viral consumption was exhibited in the North American region. Over the forecast period, the use of anti-virals in African countries is expected to increase multifold, as the majority of global companies are strategizing their HIV-based products in the emerging market.

To understand key trends, Download Sample Report

North America is Expected to Dominate the Market over the Forecast Period

North America dominated the anti-viral therapeutics market, owing to the presence of well-established market players, as well as due to the growing prevalence of HIV and hepatitis C infections. The North American market is primarily driven by factors, such as the increasing occurrence of infectious diseases, increasing geriatric population base, and growing healthcare awareness, coupled with increasing healthcare expenditure in the region. However, there are limitations to market growth in the region, which include generic erosion and patent expiration of anti-viral drugs.

To understand geography trends, Download Sample Report.

Competitive Landscape

The anti-viral therapeutics market is a fast-growing market. The current market share is majorly controlled by a few major pharmaceutical and biotechnology companies. There is a limited number of antiviral products in the market, and a large percentage of these drugs is expected to lose exclusivity in the coming future. This may be marked by the entry of generic manufacturers, expansion of market size, and lowering of market concentration.

You can also purchase parts of this report. Do you want to check out a section wise price list?

Table Of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Initiatives to Curb Viral Diseases by Public and Private Companies

      2. 4.2.2 Advancements in Molecular Biology Promoting Drug Development

      3. 4.2.3 Growing Burden of HIV Infection

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Antiviral Drug Treatment

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Drug Type

      1. 5.1.1 Herpes Anti-viral Drugs

      2. 5.1.2 Hepatitis Anti-viral Drugs

      3. 5.1.3 HIV Anti-viral Drugs

      4. 5.1.4 Influenza Anti-viral Drugs

      5. 5.1.5 Other Anti-viral Drugs

    2. 5.2 By Distribution Channel

      1. 5.2.1 Hospital Pharmacy

      2. 5.2.2 Independent Pharmacy and Drug Store

      3. 5.2.3 Online Pharmacy

    3. 5.3 By Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie Inc.

      2. 6.1.2 Bristol-Meyrs Squibb Company

      3. 6.1.3 Cipla Inc.

      4. 6.1.4 F. Hoffmann-La Roche Ltd

      5. 6.1.5 Gilead Sciences Inc.

      6. 6.1.6 GlaxoSmithKline PLC

      7. 6.1.7 Johnson & Johnson

      8. 6.1.8 Merck & Co. Inc.

      9. 6.1.9 Pfizer Inc.

      10. 6.1.10 Sanofi

  7. *List Not Exhaustive

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Related Reports